Caris Life Sciences, Inc. (CAI) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Caris Life Sciences, Inc. (CAI): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 48/100 — a percentile rank of Caris Life Sciences, Inc.’s fundamentals against Services peers, weakest on valuation. A quality ranking, not a price prediction.
| Market cap | $8.0B |
| P / E | 76.2× |
| P / S | 8.1× |
| EV / EBITDA | 44.3× |
| Gross margin | 69.7% |
| Operating margin | 15.5% |
| Net margin | 10.6% |
| Return on equity | 17.8% |
| ROIC | 52.2% |
| Revenue growth | -63.1% |
| Debt / equity | 0.7× |
| Dividend yield | 0.0% |
Is Caris Life Sciences, Inc. overvalued? P/E looks overvalued vs its 5-year range; P/S looks overvalued vs its 5-year range; EV/EBITDA looks overvalued vs its 5-year range; P/B looks overvalued vs its 5-year range.
Independent of the events above — derived from Caris Life Sciences, Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact